elotuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5072 915296-00-3

Description:

MoleculeDescription

Synonyms:

  • elotuzumab
  • empliciti
  • BMS-901608
  • HuLuc63
a humanized monoclonal antibody that selectively targets glycoproteins expressed on myeloma cells
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 11, 2016 EMA Bristol-Myers Squibb
Nov. 30, 2015 FDA BRISTOL MYERS SQUIBB
Sept. 28, 2016 PMDA Bristol-Myers Squibb

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 213.10 24.88 93 2732 82028 63404169
Plasma cell myeloma 87.45 24.88 39 2786 35866 63450331
Pneumonia 69.71 24.88 93 2732 456674 63029523
Platelet count decreased 64.48 24.88 48 2777 116074 63370123
Cytomegalovirus infection 51.75 24.88 23 2802 20929 63465268
Death 50.60 24.88 72 2753 374309 63111888
Pyrexia 48.81 24.88 80 2745 470398 63015799
Lymphocyte count decreased 46.57 24.88 24 2801 30233 63455964
Febrile infection 44.83 24.88 11 2814 1546 63484651
Neutrophil count decreased 44.60 24.88 29 2796 56377 63429820
Pneumococcal sepsis 42.04 24.88 9 2816 691 63485506
Neutropenia 36.78 24.88 42 2783 174963 63311234
Pneumonia pneumococcal 36.31 24.88 10 2815 2205 63483992
Diarrhoea 34.93 24.88 89 2736 715277 62770920
Thrombocytopenia 31.27 24.88 36 2789 151121 63335076
Febrile neutropenia 31.11 24.88 32 2793 118417 63367780
Neuropathy peripheral 30.38 24.88 31 2794 113636 63372561
Anaemia 29.09 24.88 49 2776 293381 63192816
Sepsis 27.60 24.88 34 2791 153089 63333108
Meningitis pneumococcal 25.06 24.88 5 2820 271 63485926

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 152.75 26.89 102 3591 87944 34865294
Pneumonia 107.62 26.89 159 3534 362468 34590770
Plasma cell myeloma 75.78 26.89 50 3643 41987 34911251
Febrile infection 43.57 26.89 14 3679 2197 34951041
Platelet count decreased 41.74 26.89 57 3636 119660 34833578
Keratopathy 39.97 26.89 10 3683 635 34952603
Sepsis 37.84 26.89 65 3628 166496 34786742
Campylobacter gastroenteritis 36.88 26.89 10 3683 871 34952367
Squamous cell carcinoma of skin 35.49 26.89 19 3674 10862 34942376
Neuropathy peripheral 32.61 26.89 42 3651 83221 34870017
Pneumonia respiratory syncytial viral 31.83 26.89 9 3684 914 34952324
Visceral leishmaniasis 30.62 26.89 8 3685 604 34952634
Pneumonia mycoplasmal 30.02 26.89 8 3685 652 34952586
Neutropenia 28.99 26.89 56 3637 156722 34796516
White blood cell count decreased 28.15 26.89 42 3651 95403 34857835
Influenza A virus test positive 27.11 26.89 6 3687 223 34953015
Respirovirus test positive 26.99 26.89 5 3688 74 34953164

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 324.32 27.00 167 5375 135823 79603023
Pneumonia 167.16 27.00 216 5326 660030 79078816
Platelet count decreased 102.34 27.00 94 5448 194570 79544276
Plasma cell myeloma 97.37 27.00 55 5487 53204 79685642
Pyrexia 71.67 27.00 150 5392 678559 79060287
Neutrophil count decreased 68.95 27.00 55 5487 93904 79644942
Sepsis 65.79 27.00 87 5455 269341 79469505
Neutropenia 59.85 27.00 86 5456 287624 79451222
Febrile infection 56.22 27.00 17 5525 3329 79735517
Lymphocyte count decreased 55.97 27.00 37 5505 47252 79691594
Cytomegalovirus infection 52.01 27.00 34 5508 42610 79696236
White blood cell count decreased 50.91 27.00 64 5478 188224 79550622
Anaemia 49.91 27.00 101 5441 444914 79293932
Death 48.16 27.00 115 5427 566399 79172447
Febrile neutropenia 46.46 27.00 68 5474 230931 79507915
Plasma cell myeloma recurrent 41.84 27.00 15 5527 4986 79733860
Neuropathy peripheral 39.72 27.00 49 5493 141256 79597590
Keratopathy 38.01 27.00 10 5532 1184 79737662
Septic shock 36.81 27.00 44 5498 122757 79616089
Campylobacter gastroenteritis 36.68 27.00 10 5532 1355 79737491
Thrombocytopenia 34.28 27.00 64 5478 265195 79473651
Atrial fibrillation 33.76 27.00 54 5488 197832 79541014
Squamous cell carcinoma of skin 32.59 27.00 17 5525 14016 79724830
COVID-19 28.22 27.00 44 5498 157630 79581216
Pulmonary embolism 28.12 27.00 46 5496 171608 79567238
Bacteraemia 27.93 27.00 21 5521 32803 79706043

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
FDA CS M0001357 Antibodies, Monoclonal
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000192337 SLAMF7-directed Antibody Interactions
FDA EPC N0000192338 SLAMF7-directed Immunostimulatory Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Multiple myeloma indication 109989006 DOID:9538
Relapse multiple myeloma indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
SLAM family member 7 Membrane receptor ANTIBODY BINDING Kd 8.05 IUPHAR DRUG LABEL

External reference:

IDSource
1351PE5UGS UNII
4035187 VANDF
C1832049 UMLSCUI
CHEMBL1743010 ChEMBL_ID
DB06317 DRUGBANK_ID
9074 INN_ID
C546027 MESH_SUPPLEMENTAL_RECORD_UI
8361 IUPHAR_LIGAND_ID
1726104 RXNORM
237251 MMSL
31305 MMSL
d08403 MMSL
016608 NDDF
715660001 SNOMEDCT_US
781350003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-2291 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 mg INTRAVENOUS BLA 26 sections
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-2291 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 mg INTRAVENOUS BLA 26 sections
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-2291 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 mg INTRAVENOUS BLA 26 sections
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-4522 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 400 mg INTRAVENOUS BLA 26 sections
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-4522 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 400 mg INTRAVENOUS BLA 26 sections
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-4522 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 400 mg INTRAVENOUS BLA 26 sections